<DOC>
	<DOC>NCT00766324</DOC>
	<brief_summary>To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.</brief_summary>
	<brief_title>PHA-739358 for Treatment of Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy Adequate bone marrow, liver and kidney function More than one prior chemotherapy line Uncontrolled hypertension Brain or leptomeningeal disease Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>